Saturday, October 3, 2009

Staxyn


Staxyn is a brand name of vardenafil, approved by the FDA in the following formulation(s):


STAXYN (vardenafil hydrochloride - tablet, orally disintegrating; oral)



  • Manufacturer: BAYER HLTHCARE

    Approval date: June 17, 2010

    Strength(s): 10MG [RLD]

Has a generic version of Staxyn been approved?


No. There is currently no therapeutically equivalent version of Staxyn available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Staxyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
    Patent 6,362,178
    Issued: March 26, 2002
    Inventor(s): Ulrich; Niewöhner & Mazen; Es-Sayed & Helmut; Haning & Thomas; Schenke & Karl-Heinz; Schlemmer & Jörg; Keldenich & Erwin; Bischoff & Elisabeth; Perzborn & Klaus; Dembowsky & Peter; Serno & Marc; Nowakowski
    Assignee(s): Bayer Aktiengesellschaft
    The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Patent expiration dates:

    • October 31, 2018
      ✓ 
      Patent use: TREATMENT OF ERECTILE DYSFUNCTION




  • 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
    Patent 7,696,206
    Issued: April 13, 2010
    Inventor(s): Niewöhner; Ulrich & Es-Sayed; Mazen & Haning; Helmut & Schenke; Thomas & Schlemmer; Karl-Heinz & Keldenich; Jorg & Bischoff; Erwin & Perzborn; Elisabeth & Dembowsky; Klaus & Serno; Peter & Nowakowski; Marc
    Assignee(s): Bayer Schering Pharma Aktiengesellschaft
    The application claims a compound of the formula or a salt, a hydrate, or a hydrate of a salt thereof. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of erectile dysfunction.
    Patent expiration dates:

    • October 31, 2018
      ✓ 
      Patent use: TREATMENT OF ERECTILE DYSFUNCTION



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • June 17, 2013 - NEW DOSAGE FORM

See also...

  • Staxyn Consumer Information (Drugs.com)
  • Staxyn Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
  • Staxyn Consumer Information (Cerner Multum)
  • Staxyn Advanced Consumer Information (Micromedex)
  • Vardenafil Consumer Information (Wolters Kluwer)
  • Vardenafil Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
  • Vardenafil Consumer Information (Cerner Multum)
  • Vardenafil Advanced Consumer Information (Micromedex)
  • Vardenafil Hydrochloride AHFS DI Monographs (ASHP)

No comments:

Post a Comment